Testing ATG-022 for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase I, multi-center, open-label clinical study designed to evaluate the safety, tolerability, and efficacy of ATG-022 in patients with advanced or metastatic solid tumors. The study includes a Dose Escalation Phase for all solid tumors and a Dose Expansion Phase specifically for tumors expressing Claudin 18.2 at the maximum tolerated dose. Participants will undergo assessments to determine the appropriate dosage and monitor responses to the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.
2. Aged at least 18 years as of the date of consent.
3. Histological or cytological confirmation of a solid tumor, and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or not applicable for standard therapy(ies).

   1. Dose Escalation Phase: all solid tumors.
   2. Dose Expansion Phase: Claudin 18.2 positive solid tumors.
4. Subjects should be willing to receive a biopsy at screening, if no former available tumor tissue samples within 36 months prior to participating in the study are provided.
5. At least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
6. Estimated life expectancy of a minimum of 12 weeks.
7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 .
8. Females should be using adequate contraceptive measures until 180 days after the end of treatment, should not be breastfeeding, and must have a negative pregnancy test prior to the start of dosing if of child-bearing potential or must have evidence of nonchild-bearing potential by fulfilling one of the following criteria at screening
9. Male subjects should be willing to use effective contraception, ie condoms, for the duration of the study and 180 days after the final dose of study treatment.

Exclusion Criteria:

1. Primary central nervous system disease or central nervous system metastatic disease.
2. Prior exposure to a Claudin 18.2 targeting agent.
3. Prior therapy with any chemotherapy, immunotherapy, anticancer agents, or investigational products from a previous clinical study within 28 days of the first dose of study treatment or within a period during which the investigational product or systemic anticancer treatment has not been cleared from the body (eg, a period of 5 'half-lives'.
4. Prior vaccination within 28 days of the first dose of study therapy.
5. Prior any solid organ transplant. Autologous stem cell transplant or CAR-T cell infusion \< 6 months prior to the first dose of study treatment.
6. Active infection including hepatitis B, and/or hepatitis C.
7. Known history of human immunodeficiency virus (HIV) infection.
8. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of ICF signature, with the exception of alopecia.
9. Pregnant or nursing females.
10. History of hypersensitivity or history of allergic reactions attributed to drugs with a similar chemical or biologic structure or class to ATG-022.
11. Other primary malignancies developed within 5 years prior to the first dose of the study drug, except locally curable malignancies after radical treatment .
12. In the opinion of the investigator, subject's complications, or other conditions (psychological, familial, sociological, or geographical etc.) may affect protocol compliance or may be unsuitable for participation in the study.

Where it's running

• Cabrini Health Limited
  Malvern, Australia Recruiting
• Integrated Clinical Oncology Network Pty Ltd (Icon)
  South Brisbane, Australia Recruiting
• Beijing GoBroad Hospital
  Beijing, China Recruiting
• West China Hospital, Sichuan University
  Chengdu, China Recruiting
• Fujian Cancer Hospital
  Fuzhou, China Recruiting
• Anhui Provincial Hospital
  Hefei, China Recruiting

Study contacts

• Study coordinator: Felix Li
• Email: felix.li@antengene.com
• Phone: 021-32501095

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HLX316 first-in-human dose study in advanced/metastatic solid tumors

  A first-in-human, Phase 1 study tests HLX316 to see if it is safe and tolerable and to get early signs of how it behaves in the body and whether it shows any tumor-killing activity in adults with advanced solid tumors.

  Recruiting Phase 1 Shanghai Henlius Biotech · Chongqing and 4 other locations · NCT07541534

• HLX48 first-in-human safety study in advanced solid tumors

  This early-phase study tests HLX48 in adults with advanced/metastatic solid tumors to see if it is safe and how it behaves in the body.

  Recruiting at 2 sites Phase 1 Shanghai Henlius Biotech · North Ryde, New South Wales and 6 other locations · NCT07473726

• SYS6043 treatment for advanced or metastatic solid tumors

  We will test SYS6043, a B7‑H3‑targeted antibody‑drug conjugate, in adults with advanced or metastatic solid tumors who have progressed on or are intolerant of standard therapies.

  Recruiting Phase 1/2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Beijing, Beijing Municipality · NCT07415863

• HLX37 treatment for advanced or metastatic solid tumors, including non-small cell lung cancer

  This trial tests HLX37, given alone or with chemotherapy, to see if it is safe and how the body handles it in adults with advanced or metastatic solid tumors including non-small cell lung cancer.

  Recruiting at 2 sites Early Phase 1 Shanghai Henlius Biotech · Shanghai and 1 other locations · NCT07274813

• DB-1317 for selected advanced or metastatic solid tumors

  This study will try DB-1317, given every three weeks, in adults with advanced or metastatic solid tumors that have progressed after standard treatments.

  Recruiting at 14 sites Phase 1 DualityBio Inc. · Los Angeles, California and 13 other locations · NCT07141706

• MHB088C treatment for adults with advanced solid tumors

  This study will test MHB088C to see if it is safe and shows early signs of benefit in adults with advanced or metastatic solid tumors.

  Recruiting Phase 1/2 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT07102004

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.